Clinical Trial Update: A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy Subjects [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating how the injection site and route affect the pharmacokinetic properties of faster-acting insulin aspart (FIAsp) in healthy subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Fiasp (faster-acting insulin aspart) (insulin aspart, faster-acting formulation)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Healthy | Phase 1 | Status: COMPLETED